{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:11:12Z","timestamp":1793653872550,"version":"4.5.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["267639"],"award-info":[{"award-number":["267639"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["287990"],"award-info":[{"award-number":["287990"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["262814"],"award-info":[{"award-number":["262814"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Ministry of Health and Care Services | Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["16\/00528-9"],"award-info":[{"award-number":["16\/00528-9"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Ministry of Health and Care Services | Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["15\/00779-2"],"award-info":[{"award-number":["15\/00779-2"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Ministry of Health and Care Services | Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2015012"],"award-info":[{"award-number":["2015012"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Ministry of Health and Care Services | Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2019090"],"award-info":[{"award-number":["2019090"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["5803958"],"award-info":[{"award-number":["5803958"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["189562"],"award-info":[{"award-number":["189562"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["181674"],"award-info":[{"award-number":["181674"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["197403"],"award-info":[{"award-number":["197403"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["SKGJ-MED-019"],"award-info":[{"award-number":["SKGJ-MED-019"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy. Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade. Evidence for WNT\/\u03b2-catenin signaling-mediated immune evasion is found in a subset of cancers including melanoma. Currently, there are no therapeutic strategies available for targeting WNT\/\u03b2-catenin signaling. Here we show that a specific small-molecule tankyrase inhibitor, G007-LK, decreases WNT\/\u03b2-catenin and YAP signaling in the syngeneic murine B16-F10 and Clone M-3 melanoma models and sensitizes the tumors to anti-PD-1 immune checkpoint therapy. Mechanistically, we demonstrate that the synergistic effect of tankyrase and checkpoint inhibitor treatment is dependent on loss of \u03b2-catenin in the tumor cells, anti-PD-1-stimulated infiltration of T cells into the tumor and induction of an IFN\u03b3- and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell-mediated anti-tumor immune response. Our study uncovers a combinatorial therapeutical strategy using tankyrase inhibition to overcome \u03b2-catenin-mediated resistance to immune checkpoint blockade in melanoma.\n                  <\/jats:p>","DOI":"10.1038\/s42003-020-0916-2","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T06:26:38Z","timestamp":1587709598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-6225","authenticated-orcid":false,"given":"Jo","family":"Waaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Mygland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-9262","authenticated-orcid":false,"given":"Anders","family":"Tveita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2588-5488","authenticated-orcid":false,"given":"Martin Frank","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Therese","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter Angell","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Aizenshtadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte","family":"Fauskanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshy Alam","family":"Brinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Dybing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vegard","family":"Nygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd L\u00e6ines","family":"B\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen-Marie","family":"Heintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9103-1077","authenticated-orcid":false,"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hammarstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-5725","authenticated-orcid":false,"given":"Alexandre","family":"Corthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"916_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","volume":"74","author":"WCM Dempke","year":"2017","unstructured":"Dempke, W. C. M., Fenchel, K., Uciechowski, P. & Dale, S. P. Second- and third-generation drugs for immuno-oncology treatment\u2014-the more the better? Eur. J. Cancer 74, 55\u201372 (2017).","journal-title":"Eur. J. Cancer"},{"key":"916_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"916_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals, P. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286\u2013301 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"916_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133\u2013150 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"916_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","volume":"5","author":"PA Ott","year":"2017","unstructured":"Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M. & Wolchok, J. D. Combination immunotherapy: a road map. J. Immunother. Cancer 5, 16 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"916_CR6","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 25, 3074\u20133083 (2019).","journal-title":"Clin. Cancer Res."},{"key":"916_CR7","unstructured":"Galluzzi, L., Spranger, S., Fuchs, E. & Lopez-Soto, A. WNT signaling in cancer immunosurveillance. Trends Cell Biol. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30220580 (2018)."},{"key":"916_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse, R. & Clevers, H. Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985\u2013999 (2017).","journal-title":"Cell"},{"key":"916_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","volume":"10","author":"SG Pai","year":"2017","unstructured":"Pai, S. G. et al. Wnt\/beta-catenin pathway: modulating anticancer immune response. J. Hematol. Oncol. 10, 101 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"916_CR10","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1172\/JCI95351","volume":"128","author":"J Nsengimana","year":"2018","unstructured":"Nsengimana, J. et al. beta-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J. Clin. Invest 128, 2048\u20132063 (2018).","journal-title":"J. Clin. Invest"},{"key":"916_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"916_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","volume":"18","author":"S Spranger","year":"2018","unstructured":"Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18, 139\u2013147 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"916_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"916_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321\u2013337 e310 (2018).","journal-title":"Cell"},{"key":"916_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ejmech.2017.09.030","volume":"142","author":"M Ferri","year":"2017","unstructured":"Ferri, M. et al. Targeting Wnt-driven cancers: discovery of novel tankyrase inhibitors. Eur. J. Med. Chem. 142, 506\u2013522 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"916_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 62, 50\u201360 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"916_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nature08356","volume":"461","author":"SM Huang","year":"2009","unstructured":"Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614\u2013620 (2009).","journal-title":"Nature"},{"key":"916_CR18","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1371\/journal.pbio.0000010","volume":"1","author":"E Lee","year":"2003","unstructured":"Lee, E., Salic, A., Kruger, R., Heinrich, R. & Kirschner, M. W. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 1, E10 (2003).","journal-title":"PLoS Biol."},{"key":"916_CR19","doi-asserted-by":"publisher","first-page":"6472","DOI":"10.2174\/1381612820666140630101525","volume":"20","author":"T Haikarainen","year":"2014","unstructured":"Haikarainen, T., Krauss, S. & Lehtio, L. Tankyrases: structure, function and therapeutic implications in cancer. Curr. Pharm. Des. 20, 6472\u20136488 (2014).","journal-title":"Curr. Pharm. Des."},{"key":"916_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2174\/138161213804581837","volume":"19","author":"A Voronkov","year":"2013","unstructured":"Voronkov, A. & Krauss, S. Wnt\/beta-catenin signaling and small molecule inhibitors. Curr. Pharm. Des. 19, 634\u2013664 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"916_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/0008-5472.CAN-10-1282","volume":"71","author":"J Waaler","year":"2011","unstructured":"Waaler, J. et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res. 71, 197\u2013205 (2011).","journal-title":"Cancer Res."},{"key":"916_CR22","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-11-3336","volume":"72","author":"J Waaler","year":"2012","unstructured":"Waaler, J. et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 72, 2822\u20132832 (2012).","journal-title":"Cancer Res."},{"key":"916_CR23","doi-asserted-by":"crossref","unstructured":"Lau, T. et al. A novel Tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23539443 (2013).","DOI":"10.1158\/0008-5472.CAN-12-4562"},{"key":"916_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02363-w","volume":"8","author":"A Bhardwaj","year":"2017","unstructured":"Bhardwaj, A., Yang, Y., Ueberheide, B. & Smith, S. Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation. Nat. Commun. 8, 2214 (2017).","journal-title":"Nat. Commun."},{"key":"916_CR25","first-page":"6895","volume":"16","author":"MK Kim","year":"2018","unstructured":"Kim, M. K. Novel insight into the function of tankyrase. Oncol. Lett. 16, 6895\u20136902 (2018).","journal-title":"Oncol. Lett."},{"key":"916_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12377-1","volume":"10","author":"N Li","year":"2019","unstructured":"Li, N. et al. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat. Commun. 10, 4363 (2019).","journal-title":"Nat. Commun."},{"key":"916_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.celrep.2015.09.014","volume":"13","author":"W Wang","year":"2015","unstructured":"Wang, W. et al. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 13, 524\u2013532 (2015).","journal-title":"Cell Rep."},{"key":"916_CR28","doi-asserted-by":"publisher","first-page":"28765","DOI":"10.18632\/oncotarget.9117","volume":"7","author":"A Troilo","year":"2016","unstructured":"Troilo, A. et al. Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget 7, 28765\u201328782 (2016).","journal-title":"Oncotarget"},{"key":"916_CR29","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/onc.2017.188","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng, J. et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene 36, 5829\u20135839 (2017).","journal-title":"Oncogene"},{"key":"916_CR30","doi-asserted-by":"crossref","unstructured":"Kim, M. H. et al. YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol. Res. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29382670 (2018).","DOI":"10.1158\/2326-6066.CIR-17-0320"},{"key":"916_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","volume":"167","author":"T Moroishi","year":"2016","unstructured":"Moroishi, T. et al. The hippo pathway kinases LATS1\/2 suppress cancer immunity. Cell 167, 1525\u20131539 e1517 (2016).","journal-title":"Cell"},{"key":"916_CR32","first-page":"218","volume":"35","author":"IJ Fidler","year":"1975","unstructured":"Fidler, I. J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35, 218\u2013224 (1975).","journal-title":"Cancer Res."},{"key":"916_CR33","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1084\/jem.20080099","volume":"205","author":"SA Quezada","year":"2008","unstructured":"Quezada, S. A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125\u20132138 (2008).","journal-title":"J. Exp. Med."},{"key":"916_CR34","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.4049\/jimmunol.0904114","volume":"184","author":"S Pilon-Thomas","year":"2010","unstructured":"Pilon-Thomas, S., Mackay, A., Vohra, N. & Mule, J. J. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184, 3442\u20133449 (2010).","journal-title":"J. Immunol."},{"key":"916_CR35","doi-asserted-by":"crossref","unstructured":"Voronkov, A. et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1\/2 inhibitor. J. Med. Chem. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23473363 (2013).","DOI":"10.1021\/jm4000566"},{"key":"916_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1158\/1541-7786.MCR-17-0362","volume":"16","author":"NT Solberg","year":"2018","unstructured":"Solberg, N. T. et al. TANKYRASE inhibition enhances the antiproliferative effect of PI3K and EGFR inhibition, mutually affecting beta-CATENIN and AKT signaling in colorectal cancer. Mol. Cancer Res. 16, 543\u2013553 (2018).","journal-title":"Mol. Cancer Res."},{"key":"916_CR37","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1158\/1541-7786.MCR-15-0125","volume":"13","author":"TE Thorvaldsen","year":"2015","unstructured":"Thorvaldsen, T. E. et al. Structure, dynamics, and functionality of Tankyrase inhibitor-induced degradasomes. Mol. Cancer Res. 13, 1487\u20131501 (2015).","journal-title":"Mol. Cancer Res."},{"key":"916_CR38","doi-asserted-by":"publisher","first-page":"15256","DOI":"10.1074\/jbc.M116.722967","volume":"291","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Tankyrase inhibitor sensitizes lung cancer cells to endothelial growth factor receptor (EGFR) inhibition via stabilizing angiomotins and inhibiting YAP signaling. J. Biol. Chem. 291, 15256\u201315266 (2016).","journal-title":"J. Biol. Chem."},{"key":"916_CR39","doi-asserted-by":"crossref","unstructured":"Haabeth, O.A., Bogen, B. & Corthay, A. The Matrigel Cytokine Assay. https:\/\/www.nature.com\/articles\/ncomms1239 (2011).","DOI":"10.1038\/protex.2011.237"},{"key":"916_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(92)90029-C","volume":"68","author":"Y Shinkai","year":"1992","unstructured":"Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855\u2013867 (1992).","journal-title":"Cell"},{"key":"916_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).","journal-title":"J. Transl. Med."},{"key":"916_CR42","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1158\/1538-7445.AM2017-1840","volume":"77","author":"B Zeitouni","year":"2017","unstructured":"Zeitouni, B. et al. Abstract 1840: Whole-exome somatic mutation analysis of mouse cancer models and implications for preclinical immunomodulatory drug development. Cancer Res. 77, 1840\u20131840 (2017).","journal-title":"Cancer Res."},{"key":"916_CR43","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1073\/pnas.0811902106","volume":"106","author":"AJ Chien","year":"2009","unstructured":"Chien, A. J. et al. Activated Wnt\/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA 106, 1193\u20131198 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"916_CR44","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","volume":"72","author":"ML Hartman","year":"2015","unstructured":"Hartman, M. L. & Czyz, M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol. Life Sci. 72, 1249\u20131260 (2015).","journal-title":"Cell Mol. Life Sci."},{"key":"916_CR45","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1007\/s00018-013-1324-2","volume":"70","author":"T Regad","year":"2013","unstructured":"Regad, T. Molecular and cellular pathogenesis of melanoma initiation and progression. Cell Mol. Life Sci. 70, 4055\u20134065 (2013).","journal-title":"Cell Mol. Life Sci."},{"key":"916_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7683","volume":"6","author":"A Verfaillie","year":"2015","unstructured":"Verfaillie, A. et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun. 6, 6683 (2015).","journal-title":"Nat. Commun."},{"key":"916_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek, K. S. et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290\u2013302 (2006).","journal-title":"Pigment Cell Res."},{"key":"916_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9755","volume":"6","author":"S Riesenberg","year":"2015","unstructured":"Riesenberg, S. et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat. Commun. 6, 8755 (2015).","journal-title":"Nat. Commun."},{"key":"916_CR49","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/ncb3216","volume":"17","author":"F Zanconato","year":"2015","unstructured":"Zanconato, F. et al. Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17, 1218\u20131227 (2015).","journal-title":"Nat. Cell Biol."},{"key":"916_CR50","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne, E. H. & Fisher, D. E. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 123, 2143\u20132153 (2017).","journal-title":"Cancer"},{"key":"916_CR51","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997 e924 (2018).","journal-title":"Cell"},{"key":"916_CR52","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bone.2017.10.017","volume":"106","author":"S Fujita","year":"2018","unstructured":"Fujita, S. et al. Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. Bone 106, 156\u2013166 (2018).","journal-title":"Bone"},{"key":"916_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-017-0151-6","volume":"51","author":"JH Norum","year":"2018","unstructured":"Norum, J. H. et al. The tankyrase inhibitor G007-LK inhibits small intestine LGR5(+) stem cell proliferation without altering tissue morphology. Biol. Res. 51, 3 (2018).","journal-title":"Biol. Res."},{"key":"916_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont, S. et al. Role of YAP\/TAZ in mechanotransduction. Nature 474, 179\u2013183 (2011).","journal-title":"Nature"},{"key":"916_CR55","doi-asserted-by":"publisher","first-page":"W272","DOI":"10.1093\/nar\/gkw398","volume":"44","author":"K Labun","year":"2016","unstructured":"Labun, K., Montague, T. G., Gagnon, J. A., Thyme, S. B. & Valen, E. CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res. 44, W272\u2013276 (2016).","journal-title":"Nucleic Acids Res."},{"key":"916_CR56","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"916_CR57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"916_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1074-7613(00)80091-6","volume":"11","author":"S Garcia","year":"1999","unstructured":"Garcia, S., DiSanto, J. & Stockinger, B. Following the development of a CD4 T cell response in vivo: from activation to memory formation. Immunity 11, 163\u2013171 (1999).","journal-title":"Immunity"},{"key":"916_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1365-2567.2002.01408.x","volume":"106","author":"SI Mannering","year":"2002","unstructured":"Mannering, S. I., Zhong, J. & Cheers, C. T-cell activation, proliferation and apoptosis in primary Listeria monocytogenes infection. Immunology 106, 87\u201395 (2002).","journal-title":"Immunology"},{"key":"916_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"916_CR61","first-page":"bar030","volume":"2011","author":"RJ Kinsella","year":"2011","unstructured":"Kinsella, R. J. et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxf.) 2011, bar030 (2011).","journal-title":"Database (Oxf.)"},{"key":"916_CR62","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nmeth.4324","volume":"14","author":"H Pimentel","year":"2017","unstructured":"Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat. Methods 14, 687\u2013690 (2017).","journal-title":"Nat. Methods"},{"key":"916_CR63","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"916_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"916_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinforma. 11, 367 (2010).","journal-title":"BMC Bioinforma."},{"key":"916_CR66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"916_CR67","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44, e108\u2013e108 (2016).","journal-title":"Nucleic Acids Res."},{"key":"916_CR68","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777\u2013D783 (2017).","journal-title":"Nucleic Acids Res."},{"key":"916_CR69","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164\u2013e164 (2010).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-0916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-0916-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-0916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:00:13Z","timestamp":1670360413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-0916-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-0916-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/526343","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"1 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.W. and S.K. hold patents related to tankyrase inhibitor therapy and these authors declare no additional interests. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}